Pharmafile Logo

Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis


You can probably remember at least one of your friends in school who was always scratching and suffered from red, scaly skin rashes, perhaps on their elbows or backs of their knees, and if they were really unlucky, on their face? This child may have disliked going to the swimming pool and particularly suffered from flare-ups during cold winter or hot summer months. They might have tried to cover up their skin with long-sleeved clothing, or hide their face to avoid being stared at.

Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring for children with the disease. It also puts a considerable burden on healthcare resources. AD affects up to 20% of children and around 3% of adults worldwide and its prevalence is still increasing, especially in some lower income countries in Asia and Latin America. The majority of patients start to experience symptoms before they reach 5 years of age and often suffer from asthma or other allergies. Severity varies widely – some people might just suffer from a light rash on a few areas of the body and might get better as they get older, whilst others can suffer from very dry, bleeding and sore skin all over, with regular painful flare-ups, which continue into adulthood. In the US, physicians typically use the Body Surface Index to assess severity of the disease. Around 65% of patients in the US are recognised as suffering from moderate-severe eczema. Severe patients can suffer from more than 15 flare-ups per year, lasting two weeks or more…

Read the full article: http://bit.ly/2I9EbcK

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Video: Immuno-oncology therapies

Immuno-oncology therapies which harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. However, these therapies come with a very high...

Event: EULAR Annual European Congress of Rheumatology 2016

We are delighted to be attending the EULAR Annual European Congress of Rheumatology in June. Representing Research Partnership is Business Development Manager, Fara Mboge. He will be on hand to...

Forever Angels achievements and development plan for 2016

Research Partnership is proud to support Forever Angels in their mission of caring for and improving the lives of orphans and abandoned infants in Tanzania

The Opportunity for Women’s Health in Emerging Markets

Published in eyeforpharma April 2016 by Rachel Howard

Video: Storytelling in healthcare market research

Within the pharmaceutical industry, there is an increasing need for market research teams to share the insights with their key internal stakeholders, from marketing and brand managers to sales reps...

Promotions and new appointments across our global offices

Research Partnership is delighted to announce promotions and new starters in the UK and further appointments in the US and Singapore offices

Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?

In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy...

Webcast: Understanding the Chronic Disease Patient Journey in Emerging Markets

In emerging markets where primary care systems do not exist, the patient is the only constant in the journey

Living with Crohn’s Report

Are you looking for a deeper understanding of the emotional needs, behaviours and treatment programmes of patients living with Crohn’s Disease?

Infographic: Research Partnership

Our latest infographic offers an overview of some key facts and figures about the company, its services and capabilities.